Which hip patients suit both injections?

Two injections in the same hip joint is not a default protocol — it describes a specific clinical presentation where a single hip carries two structurally distinct problems that respond to different mechanisms.

The scenario is this: a patient presents with a focal Grade III or IV articular cartilage defect on the femoral head or acetabulum — a discrete, bordered lesion in otherwise viable surrounding cartilage — alongside background diffuse osteoarthritis affecting the broader joint surface at Kellgren-Lawrence Grade III or IV. These are not variations of the same pathology. A focal defect is a contained structural gap; diffuse OA is generalised surface breakdown across the whole joint environment. Neither condition is a subset of the other.

ChondroFiller™ is an injectable Type I collagen scaffold designed to address focal structural defects by recruiting the patient's own cells into the lesion. Arthrosamid is a non-biodegradable polyacrylamide hydrogel that cushions a diffusely worn joint surface. When both pathologies coexist in one hip, the mechanistic case for using both is that each targets a different layer of the same joint's problem — not that one reinforces the other.

This applies to a defined patient subset, not to hip osteoarthritis generally. Establishing that both components are truly present requires MRI review and a consultant assessment; a combination plan is formed only when imaging confirms dual pathology in the same hip.

What ChondroFiller™ does to a focal hip cartilage defect

The scaffold works not by injecting cartilage but by giving the body a framework to build with. ChondroFiller™ is a CE-marked Class III medical device — an acellular collagen scaffold derived from murine Type I collagen — that gels in situ once placed inside the defect site. A three-dimensional matrix forms within the void, and the patient's own progenitor cells, drawn from the surrounding synovium and subchondral bone, migrate in and differentiate into chondrocytes. No donor cells are delivered; the process is acellular matrix-induced chondrogenesis.

The hip is explicitly within the device's approved indications, alongside the knee, shoulder, and ankle. Delivery is an outpatient ultrasound-guided injection requiring no general anaesthetic and no surgical incision.

The action is localised: the scaffold fills the structural deficit from within the lesion outward rather than coating the joint surface as a whole. This bottom-up geometry is what gives ChondroFiller™ its distinct role when a hip presents with both a focal defect and broader degeneration.

On outcomes in the hip, modified Harris Hip Score (mHHS) improvements of approximately 30 points have been reported in treated patients — a result consistent with clinically meaningful thresholds. MOCART scores in studied populations range from 70 to 87, indicating substantial defect filling and progressive repair-tissue integration. The more extensive published evidence base is in the knee, where IKDC scores improved by 30–32 points over 12–36 months in prospective follow-up, with MOCART progressing from 65.3 at four weeks to 81.6 at one year. Hip-specific outcome data are still accumulating relative to that larger record, though the hip indication remains within the device's approved scope.

How Arthrosamid cushions the osteoarthritic hip joint

Arthrosamid's regulatory approval covers knee osteoarthritis in adults — CE-marked in Europe since 2021. Its use in the hip is off-label, a material fact that belongs in any informed consent discussion and that patients considering this route should be aware of before proceeding.

The hydrogel is composed of 2.5% cross-linked polyacrylamide and 97.5% non-pyrogenic water, administered as a single 6 mL intra-articular injection. Unlike a temporary injectate, it is non-biodegradable: it is designed to remain within the joint rather than degrade over time. Integration begins within approximately 10 to 14 days, during which synovial cells proliferate into the gel. Histopathological studies show that by around 30 days a stable sub-synovial layer has formed — a gel-traversed connective tissue structure with its own vascular supply, covered by regenerated synovial lining. This is characterised as a low-level, macrophage-driven foreign body response rather than active inflammation.

The outcome is a persistent cushioning layer across the interior joint lining, absorbing friction over the joint surface as a whole. This is not a regenerative effect. Arthrosamid does not scaffold a cartilage lesion, does not recruit repair cells, and does not aim to restore lost cartilage volume. Its clinical target is diffuse, global joint degeneration, and its goal is sustained symptomatic relief rather than structural repair.

No published hip-specific trial data exist for Arthrosamid at the time of writing; the rationale for its use in the hip rests on mechanistic extrapolation from knee evidence — a distinction both patients and referring clinicians should understand from the outset.

Why the two mechanisms address different layers of the same problem

Treating the hip's focal defect and its background osteoarthritis as a single problem is the clinical error the combination approach is designed to avoid. Each pathology sits in a different tier of the treatment hierarchy used at formal suitability assessment — cushioning on one level, scaffold-based structural repair on another — and a hip carrying both will not be fully addressed by a product aimed at only one tier.

A combination plan is one possible output of that assessment, not a standard starting point. Before it is recommended, imaging must confirm that both pathologies genuinely co-exist. If MRI shows only diffuse OA without a discrete bordered lesion, the scaffold tier is not indicated; if the joint carries a focal defect without significant surrounding degeneration, the cushioning tier adds little. The two-injection pathway is justified precisely when the hip presents with distinct problems at both levels simultaneously.

When both are confirmed, the delivery sequence matters in practice. Each injection is placed at a separate outpatient appointment under image guidance — the same hip approached at different stages, each product directed at its distinct anatomical target. No theatre time or general anaesthetic is involved for either step.

The rationale for combining both is built on mechanistic inference and extrapolation from two separate evidence bodies. No published randomised trial or case series has evaluated this specific dual-injection approach in the hip joint, and the off-label status of Arthrosamid in the hip adds a further consideration that consultant assessment must address before any plan is agreed. Clinically coherent and logistically feasible are not the same as established protocol.

Assessment, sequencing, and what to expect at appointments

The starting point is a consultant-led appointment at which MRI is reviewed: not to establish a diagnosis from scratch, but to map the focal defect's border integrity and extent alongside the degree of surrounding degeneration — the imaging findings that determine whether both treatment tiers are warranted.

Where a combination plan is agreed, the two injections are staged across separate outpatient sessions. The interval between them reflects the consultant's clinical judgement rather than a fixed protocol; no mandated gap is specified in the available evidence. Each session targets a distinct anatomical problem, and post-injection aftercare will differ between the two products accordingly. Arthrosamid's protocol includes seven days of NSAID cover to accompany the early hydrogel integration process; ChondroFiller aftercare is directed at protecting the collagen scaffold during the initial cell-migration phase. Patients should expect separate written guidance for each step rather than a single unified recovery plan.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment; initial consultation, MRI review, and suitability assessment are available in Sleaford and Grantham for patients across Lincolnshire and the wider non-London catchment.

Evidence gaps, off-label use, and cost — what to weigh before deciding

Both treatments are self-funded private procedures — neither is NHS-funded, and neither Bupa nor AXA covers them as standard. A combined course starts at approximately £6,000 as a guide cost, with the final figure varying according to defect extent and clinic. Patients should request a written cost estimate at the suitability consultation rather than treating the floor figure as a fixed price.

The broader evidence context is worth holding in one place rather than scattered across a longer article. The combination pathway rests on two separate evidence bodies — one for each agent — rather than a dedicated combination trial, and Arthrosamid's CE mark covers knee osteoarthritis only, so its use in the hip rests on clinical judgement rather than regulatory approval for that joint. Neither fact disqualifies the pathway, but both shape the conversation a patient should expect to have before consenting: informed consent here means understanding the mechanistic rationale alongside the current limits of the evidence.

On the imaging side, the findings that make a combination plan worth pursuing are specific: a bordered Grade III or IV lesion on the femoral head or acetabulum, alongside Kellgren-Lawrence Grade III or IV background degeneration in the surrounding joint. When MRI shows only one of these — diffuse wear without a discrete bordered defect, or an isolated lesion without significant surrounding degeneration — a single-agent approach is likely more appropriate than a dual-injection pathway. That distinction is what a formal hip assessment is designed to establish.